AR093402A1 - Producto de comicronizacion que comprende acetato de ulipristal - Google Patents

Producto de comicronizacion que comprende acetato de ulipristal

Info

Publication number
AR093402A1
AR093402A1 ARP130104089A ARP130104089A AR093402A1 AR 093402 A1 AR093402 A1 AR 093402A1 AR P130104089 A ARP130104089 A AR P130104089A AR P130104089 A ARP130104089 A AR P130104089A AR 093402 A1 AR093402 A1 AR 093402A1
Authority
AR
Argentina
Prior art keywords
ulipristal acetate
comicronization
product
comicronization product
present
Prior art date
Application number
ARP130104089A
Other languages
English (en)
Original Assignee
Laboratoire Hra-Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Hra-Pharma filed Critical Laboratoire Hra-Pharma
Publication of AR093402A1 publication Critical patent/AR093402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Circuit Arrangements For Discharge Lamps (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Thyristors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente tiene por objeto un producto de comicronización que comprende una sustancia activa elegida entre el grupo constituido por el acetato de ulipristal, un metabolito del acetato de ulipristal y sus mezclas, y un tensioactivo sólido aceptable desde el punto de vista farmacéutico. La presente se refiere también a una composición farmacéutica que comprende dicho producto de comicronización y sus utilizaciones terapéuticas.
ARP130104089A 2012-11-08 2013-11-07 Producto de comicronizacion que comprende acetato de ulipristal AR093402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1260603A FR2997627B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant de l'ulipristal acetate

Publications (1)

Publication Number Publication Date
AR093402A1 true AR093402A1 (es) 2015-06-03

Family

ID=47878175

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104089A AR093402A1 (es) 2012-11-08 2013-11-07 Producto de comicronizacion que comprende acetato de ulipristal

Country Status (30)

Country Link
US (2) US9610293B2 (es)
EP (1) EP2916871B1 (es)
JP (1) JP2015536968A (es)
KR (1) KR20150093170A (es)
CN (1) CN104902928B (es)
AR (1) AR093402A1 (es)
AU (1) AU2013343320B2 (es)
BR (1) BR112015010271B1 (es)
CA (1) CA2890272A1 (es)
CR (1) CR20150297A (es)
CY (1) CY1119542T1 (es)
DK (1) DK2916871T3 (es)
EA (1) EA027641B1 (es)
EC (1) ECSP15022442A (es)
ES (1) ES2606307T3 (es)
FR (1) FR2997627B1 (es)
GE (1) GEP201706637B (es)
HR (1) HRP20161624T1 (es)
HU (1) HUE031911T2 (es)
LT (1) LT2916871T (es)
MD (1) MD4563C1 (es)
MX (1) MX363699B (es)
PL (1) PL2916871T3 (es)
PT (1) PT2916871T (es)
RS (1) RS55429B1 (es)
SI (1) SI2916871T1 (es)
SM (1) SMT201600445B (es)
TW (1) TWI617325B (es)
UA (1) UA117465C2 (es)
WO (1) WO2014072646A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
CN103923154B (zh) * 2013-01-16 2017-09-26 杭州容立医药科技有限公司 醋酸乌利司他的共晶及制备方法
CN105663140A (zh) * 2014-11-21 2016-06-15 四川海思科制药有限公司 一种含醋酸乌利司他的药物组合物及其制备方法
CN104865215A (zh) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 一种醋酸乌利司他片剂及其溶出度测定方法
CN105919150A (zh) * 2016-05-12 2016-09-07 高洁珺 一种代替压片工艺中化工添加剂的方法
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
WO2008037044A1 (en) 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
RU2465907C2 (ru) 2006-12-20 2012-11-10 Тева Вимен'С Хелс, Инк. Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм
JP2010514793A (ja) * 2006-12-28 2010-05-06 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンのバイオアベイラビリティを改善するための方法および製剤
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
WO2010119029A1 (en) 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Method for on-demand contraception
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate

Also Published As

Publication number Publication date
PL2916871T3 (pl) 2017-02-28
ES2606307T3 (es) 2017-03-23
DK2916871T3 (da) 2017-01-02
PT2916871T (pt) 2016-12-15
GEP201706637B (en) 2017-03-10
KR20150093170A (ko) 2015-08-17
CY1119542T1 (el) 2018-03-07
TW201427718A (zh) 2014-07-16
MD20150053A2 (ro) 2015-10-31
EA027641B1 (ru) 2017-08-31
EP2916871A1 (fr) 2015-09-16
CA2890272A1 (fr) 2014-05-15
CR20150297A (es) 2015-08-14
US20150290218A1 (en) 2015-10-15
US9610293B2 (en) 2017-04-04
UA117465C2 (uk) 2018-08-10
AU2013343320B2 (en) 2018-03-08
EA201500513A1 (ru) 2015-08-31
CN104902928B (zh) 2018-10-23
ECSP15022442A (es) 2016-01-29
AU2013343320A1 (en) 2015-06-04
MD4563B1 (ro) 2018-05-31
EP2916871B1 (fr) 2016-09-14
MX2015005762A (es) 2016-02-11
CN104902928A (zh) 2015-09-09
BR112015010271B1 (pt) 2020-04-22
SMT201600445B (it) 2017-01-10
RS55429B1 (sr) 2017-04-28
FR2997627A1 (fr) 2014-05-09
MD4563C1 (ro) 2018-12-31
LT2916871T (lt) 2016-12-27
SI2916871T1 (sl) 2017-03-31
WO2014072646A1 (fr) 2014-05-15
FR2997627B1 (fr) 2015-01-16
HRP20161624T1 (hr) 2017-01-27
JP2015536968A (ja) 2015-12-24
MX363699B (es) 2019-03-28
TWI617325B (zh) 2018-03-11
HUE031911T2 (en) 2017-08-28
US20170157146A1 (en) 2017-06-08
BR112015010271A2 (pt) 2017-07-11
BR112015010271A8 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
PE20140255A1 (es) Tableta dispersable en forma oral
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
HK1221418A1 (zh) 释放修饰药物的水凝胶-连接的前药
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
EA201690207A1 (ru) Композиция традиционной китайской медицины и препарат из нее и их применение
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
IN2014MN02236A (es)
IN2013MU00711A (es)
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX2015017202A (es) Formulacion de liberacion modificada.
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
CL2015002832A1 (es) Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa.
MX2017008983A (es) Composición farmaceútica de sulfonamida.
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
WO2015031198A3 (en) Bendamustine pharmaceutical compositions
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
CL2015000290A1 (es) Compuestos derivados de ariletinilo. moduladores alostéricos del receptor de glutamato mglur5; proceso de obtencion; composicion farmaceuticas: y su uso en el tratamiento o prevencon de la esquizofenia, enfermedades cognitivas, sindrome de x fragil o autismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure